Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died

Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide

If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19Continue reading

PFIZER AND BIONTECH TO PROVIDE 500 MILLION DOSES OF COVID-19 VACCINE TO U.S. GOVERNMENT FOR DONATION TO POOREST NATIONS

  • U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022
  • Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX Facility
  • Effort is part of the companies’ recent pledge of two billion doses to ensure global equitable access to the vaccine

Continue reading